Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan

Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Shin-ichi Yamada [verfasserIn] Hiroshi Kurita [verfasserIn] Akira Tanaka [verfasserIn] Masaru Miyata [verfasserIn] Yoshinari Morimoto [verfasserIn] Akira Yamaguchi [verfasserIn] Souichi Yanamoto [verfasserIn] Hiromasa Yoshikawa [verfasserIn] Yutaka Imai [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Angiogenesis inhibitor VEGF Oral complication Osteonecrosis of the jaw Hemorrhage

Übergeordnetes Werk:	In: Journal of Dental Sciences - Elsevier, 2017, 16(2021), 1, Seite 375-379
Übergeordnetes Werk:	volume:16 ; year:2021 ; number:1 ; pages:375-379

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.jds.2020.01.004

Katalog-ID:	DOAJ055194257

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ055194257
003	DE-627
005	20230503145109.0
007	cr uuu---uuuuu
008	230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.jds.2020.01.004 \|2 doi
035			\|a (DE-627)DOAJ055194257
035			\|a (DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RK1-715
100	0		\|a Shin-ichi Yamada \|e verfasserin \|4 aut
245	1	0	\|a Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications.
650		4	\|a Angiogenesis inhibitor
650		4	\|a VEGF
650		4	\|a Oral complication
650		4	\|a Osteonecrosis of the jaw
650		4	\|a Hemorrhage
653		0	\|a Dentistry
700	0		\|a Hiroshi Kurita \|e verfasserin \|4 aut
700	0		\|a Akira Tanaka \|e verfasserin \|4 aut
700	0		\|a Masaru Miyata \|e verfasserin \|4 aut
700	0		\|a Yoshinari Morimoto \|e verfasserin \|4 aut
700	0		\|a Akira Yamaguchi \|e verfasserin \|4 aut
700	0		\|a Souichi Yanamoto \|e verfasserin \|4 aut
700	0		\|a Hiromasa Yoshikawa \|e verfasserin \|4 aut
700	0		\|a Yutaka Imai \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Dental Sciences \|d Elsevier, 2017 \|g 16(2021), 1, Seite 375-379 \|w (DE-627)604074778 \|w (DE-600)2502332-9 \|x 19917902 \|7 nnns
773	1	8	\|g volume:16 \|g year:2021 \|g number:1 \|g pages:375-379
856	4	0	\|u https://doi.org/10.1016/j.jds.2020.01.004 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S199179022030026X \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1991-7902 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 16 \|j 2021 \|e 1 \|h 375-379

Indexfelder

author_variant	s i y siy h k hk a t at m m mm y m ym a y ay s y sy h y hy y i yi
matchkey_str	article:19917902:2021----::usinarsreoagoeeiihbtreaeoacmlctosaeo
hierarchy_sort_str	2021
callnumber-subject-code	RK
publishDate	2021
allfields	10.1016/j.jds.2020.01.004 doi (DE-627)DOAJ055194257 (DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26 DE-627 ger DE-627 rakwb eng RK1-715 Shin-ichi Yamada verfasserin aut Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications. Angiogenesis inhibitor VEGF Oral complication Osteonecrosis of the jaw Hemorrhage Dentistry Hiroshi Kurita verfasserin aut Akira Tanaka verfasserin aut Masaru Miyata verfasserin aut Yoshinari Morimoto verfasserin aut Akira Yamaguchi verfasserin aut Souichi Yanamoto verfasserin aut Hiromasa Yoshikawa verfasserin aut Yutaka Imai verfasserin aut In Journal of Dental Sciences Elsevier, 2017 16(2021), 1, Seite 375-379 (DE-627)604074778 (DE-600)2502332-9 19917902 nnns volume:16 year:2021 number:1 pages:375-379 https://doi.org/10.1016/j.jds.2020.01.004 kostenfrei https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26 kostenfrei http://www.sciencedirect.com/science/article/pii/S199179022030026X kostenfrei https://doaj.org/toc/1991-7902 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2021 1 375-379
spelling	10.1016/j.jds.2020.01.004 doi (DE-627)DOAJ055194257 (DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26 DE-627 ger DE-627 rakwb eng RK1-715 Shin-ichi Yamada verfasserin aut Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications. Angiogenesis inhibitor VEGF Oral complication Osteonecrosis of the jaw Hemorrhage Dentistry Hiroshi Kurita verfasserin aut Akira Tanaka verfasserin aut Masaru Miyata verfasserin aut Yoshinari Morimoto verfasserin aut Akira Yamaguchi verfasserin aut Souichi Yanamoto verfasserin aut Hiromasa Yoshikawa verfasserin aut Yutaka Imai verfasserin aut In Journal of Dental Sciences Elsevier, 2017 16(2021), 1, Seite 375-379 (DE-627)604074778 (DE-600)2502332-9 19917902 nnns volume:16 year:2021 number:1 pages:375-379 https://doi.org/10.1016/j.jds.2020.01.004 kostenfrei https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26 kostenfrei http://www.sciencedirect.com/science/article/pii/S199179022030026X kostenfrei https://doaj.org/toc/1991-7902 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2021 1 375-379
allfields_unstemmed	10.1016/j.jds.2020.01.004 doi (DE-627)DOAJ055194257 (DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26 DE-627 ger DE-627 rakwb eng RK1-715 Shin-ichi Yamada verfasserin aut Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications. Angiogenesis inhibitor VEGF Oral complication Osteonecrosis of the jaw Hemorrhage Dentistry Hiroshi Kurita verfasserin aut Akira Tanaka verfasserin aut Masaru Miyata verfasserin aut Yoshinari Morimoto verfasserin aut Akira Yamaguchi verfasserin aut Souichi Yanamoto verfasserin aut Hiromasa Yoshikawa verfasserin aut Yutaka Imai verfasserin aut In Journal of Dental Sciences Elsevier, 2017 16(2021), 1, Seite 375-379 (DE-627)604074778 (DE-600)2502332-9 19917902 nnns volume:16 year:2021 number:1 pages:375-379 https://doi.org/10.1016/j.jds.2020.01.004 kostenfrei https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26 kostenfrei http://www.sciencedirect.com/science/article/pii/S199179022030026X kostenfrei https://doaj.org/toc/1991-7902 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2021 1 375-379
allfieldsGer	10.1016/j.jds.2020.01.004 doi (DE-627)DOAJ055194257 (DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26 DE-627 ger DE-627 rakwb eng RK1-715 Shin-ichi Yamada verfasserin aut Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications. Angiogenesis inhibitor VEGF Oral complication Osteonecrosis of the jaw Hemorrhage Dentistry Hiroshi Kurita verfasserin aut Akira Tanaka verfasserin aut Masaru Miyata verfasserin aut Yoshinari Morimoto verfasserin aut Akira Yamaguchi verfasserin aut Souichi Yanamoto verfasserin aut Hiromasa Yoshikawa verfasserin aut Yutaka Imai verfasserin aut In Journal of Dental Sciences Elsevier, 2017 16(2021), 1, Seite 375-379 (DE-627)604074778 (DE-600)2502332-9 19917902 nnns volume:16 year:2021 number:1 pages:375-379 https://doi.org/10.1016/j.jds.2020.01.004 kostenfrei https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26 kostenfrei http://www.sciencedirect.com/science/article/pii/S199179022030026X kostenfrei https://doaj.org/toc/1991-7902 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2021 1 375-379
allfieldsSound	10.1016/j.jds.2020.01.004 doi (DE-627)DOAJ055194257 (DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26 DE-627 ger DE-627 rakwb eng RK1-715 Shin-ichi Yamada verfasserin aut Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications. Angiogenesis inhibitor VEGF Oral complication Osteonecrosis of the jaw Hemorrhage Dentistry Hiroshi Kurita verfasserin aut Akira Tanaka verfasserin aut Masaru Miyata verfasserin aut Yoshinari Morimoto verfasserin aut Akira Yamaguchi verfasserin aut Souichi Yanamoto verfasserin aut Hiromasa Yoshikawa verfasserin aut Yutaka Imai verfasserin aut In Journal of Dental Sciences Elsevier, 2017 16(2021), 1, Seite 375-379 (DE-627)604074778 (DE-600)2502332-9 19917902 nnns volume:16 year:2021 number:1 pages:375-379 https://doi.org/10.1016/j.jds.2020.01.004 kostenfrei https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26 kostenfrei http://www.sciencedirect.com/science/article/pii/S199179022030026X kostenfrei https://doaj.org/toc/1991-7902 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2021 1 375-379
language	English
source	In Journal of Dental Sciences 16(2021), 1, Seite 375-379 volume:16 year:2021 number:1 pages:375-379
sourceStr	In Journal of Dental Sciences 16(2021), 1, Seite 375-379 volume:16 year:2021 number:1 pages:375-379
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Angiogenesis inhibitor VEGF Oral complication Osteonecrosis of the jaw Hemorrhage Dentistry
isfreeaccess_bool	true
container_title	Journal of Dental Sciences
authorswithroles_txt_mv	Shin-ichi Yamada @@aut@@ Hiroshi Kurita @@aut@@ Akira Tanaka @@aut@@ Masaru Miyata @@aut@@ Yoshinari Morimoto @@aut@@ Akira Yamaguchi @@aut@@ Souichi Yanamoto @@aut@@ Hiromasa Yoshikawa @@aut@@ Yutaka Imai @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	604074778
id	DOAJ055194257
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ055194257</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503145109.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jds.2020.01.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ055194257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RK1-715</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Shin-ichi Yamada</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Angiogenesis inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">VEGF</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oral complication</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hemorrhage</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dentistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Kurita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akira Tanaka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masaru Miyata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshinari Morimoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akira Yamaguchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Souichi Yanamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiromasa Yoshikawa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yutaka Imai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Dental Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">16(2021), 1, Seite 375-379</subfield><subfield code="w">(DE-627)604074778</subfield><subfield code="w">(DE-600)2502332-9</subfield><subfield code="x">19917902</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:375-379</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jds.2020.01.004</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S199179022030026X</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1991-7902</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">375-379</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Shin-ichi Yamada
spellingShingle	Shin-ichi Yamada misc RK1-715 misc Angiogenesis inhibitor misc VEGF misc Oral complication misc Osteonecrosis of the jaw misc Hemorrhage misc Dentistry Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan
authorStr	Shin-ichi Yamada
ppnlink_with_tag_str_mv	@@773@@(DE-627)604074778
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RK1-715
illustrated	Not Illustrated
issn	19917902
topic_title	RK1-715 Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan Angiogenesis inhibitor VEGF Oral complication Osteonecrosis of the jaw Hemorrhage
topic	misc RK1-715 misc Angiogenesis inhibitor misc VEGF misc Oral complication misc Osteonecrosis of the jaw misc Hemorrhage misc Dentistry
topic_unstemmed	misc RK1-715 misc Angiogenesis inhibitor misc VEGF misc Oral complication misc Osteonecrosis of the jaw misc Hemorrhage misc Dentistry
topic_browse	misc RK1-715 misc Angiogenesis inhibitor misc VEGF misc Oral complication misc Osteonecrosis of the jaw misc Hemorrhage misc Dentistry
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Dental Sciences
hierarchy_parent_id	604074778
hierarchy_top_title	Journal of Dental Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)604074778 (DE-600)2502332-9
title	Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan
ctrlnum	(DE-627)DOAJ055194257 (DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26
title_full	Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan
author_sort	Shin-ichi Yamada
journal	Journal of Dental Sciences
journalStr	Journal of Dental Sciences
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	375
author_browse	Shin-ichi Yamada Hiroshi Kurita Akira Tanaka Masaru Miyata Yoshinari Morimoto Akira Yamaguchi Souichi Yanamoto Hiromasa Yoshikawa Yutaka Imai
container_volume	16
class	RK1-715
format_se	Elektronische Aufsätze
author-letter	Shin-ichi Yamada
doi_str_mv	10.1016/j.jds.2020.01.004
author2-role	verfasserin
title_sort	questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in japan
callnumber	RK1-715
title_auth	Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan
abstract	Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications.
abstractGer	Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications.
abstract_unstemmed	Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2004 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan
url	https://doi.org/10.1016/j.jds.2020.01.004 https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26 http://www.sciencedirect.com/science/article/pii/S199179022030026X https://doaj.org/toc/1991-7902
remote_bool	true
author2	Hiroshi Kurita Akira Tanaka Masaru Miyata Yoshinari Morimoto Akira Yamaguchi Souichi Yanamoto Hiromasa Yoshikawa Yutaka Imai
author2Str	Hiroshi Kurita Akira Tanaka Masaru Miyata Yoshinari Morimoto Akira Yamaguchi Souichi Yanamoto Hiromasa Yoshikawa Yutaka Imai
ppnlink	604074778
callnumber-subject	RK - Dentistry
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.jds.2020.01.004
callnumber-a	RK1-715
up_date	2024-07-03T13:32:57.019Z
_version_	1803564956539420672
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ055194257</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503145109.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jds.2020.01.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ055194257</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf2b96dbe0625401bb7da3ced287cbf26</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RK1-715</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Shin-ichi Yamada</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear. The purpose of this study was to investigate the contents of dental treatment-related complications in Japanese patients during molecular targeted therapy. Materials and methods: The nation-wide survey of dental treatment related complications was performed by the Japanese Society of Dentistry for Medically Compromised Patient as retrospective cohort study. Results: Among 212 dentists, 87.3% recognized the possibility of dental treatments related complications in patients with angiogenesis inhibitors. The oral adverse events including dental treatment-related complications associated with angiogenesis inhibitors were 79 cases. In patients with angiogenesis inhibitors, 73.4% of patients were administrated with bevacizumab. The average administration period of angiogenesis inhibitors was 14.0 ± 10.0 months. As the dental treatment related complications, delayed wound healing was most commonly seen in 45 patients (57.0%), followed by osteonecrosis of the jaw in 25 (31.6%). The triggered factor of complications was tooth extraction in 51 cases (96.2%). Conclusion: The extraction of the tooth with pre-existing inflammation may be suggested as one of risk factors for angiogenesis inhibitor-related dental treatment complications.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Angiogenesis inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">VEGF</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oral complication</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hemorrhage</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dentistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiroshi Kurita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akira Tanaka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Masaru Miyata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yoshinari Morimoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Akira Yamaguchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Souichi Yanamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hiromasa Yoshikawa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yutaka Imai</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Dental Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">16(2021), 1, Seite 375-379</subfield><subfield code="w">(DE-627)604074778</subfield><subfield code="w">(DE-600)2502332-9</subfield><subfield code="x">19917902</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:375-379</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jds.2020.01.004</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f2b96dbe0625401bb7da3ced287cbf26</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S199179022030026X</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1991-7902</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">375-379</subfield></datafield></record></collection>
score	7.400401

Nicht das Richtige dabei?

Schreiben Sie uns!

Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?